DC31024 · Updated 27 October 2026
SM-86 (Lipid 5)
Instructions for Use
Before use
Check the supplied lot number, batch COA, approved SDS, quantity and retest date. Pure form: −20 °C, 1 year; In solvent: −80 °C, 6 months; −20 °C, 1 month. Sealed and protected from light.
For small quantities of viscous or oily lipid, volumetric transfer can reduce weighing losses. Confirm solvent compatibility and solubility before preparing a stock; calculated volumes do not establish solubility.
Stock-solution planning
Volume (mL) = mass (mg) × 1000 / [molecular weight × concentration (mM)].
| Mass | 10 mM | 20 mM |
|---|---|---|
| 10 mg | 1.4081 mL | 0.7041 mL |
| 25 mg | 3.5203 mL | 1.7602 mL |
| 50 mg | 7.0406 mL | 3.5203 mL |
| 100 mg | 14.0812 mL | 7.0406 mL |
Literature formulation reference
| Component | DC Chemicals product | Molecular weight | Molar ratio | Mass at 1 µmol total lipid (mg) |
|---|---|---|---|---|
| SM-86 | DC31024 | 710.165 | Not disclosed | Not calculable from disclosed data |
| DSPC | DC57005 | 790.15 | Not disclosed | Not calculable from disclosed data |
| Cholesterol | DCD-041 | 386.65 | Not disclosed | Not calculable from disclosed data |
| OL-56 (PEG-lipid) | Not uniquely mapped | Not established | Not disclosed | Not calculable from disclosed data |
The four components are explicitly named, but their molar proportions, N/P ratio and lipid:RNA mass ratio are not disclosed. OL-56 cannot be replaced by DMG-PEG2000 when describing this study. Supplementary Table 9 separately lists SM-86/OL-56 and SM-86/DMG formulations; these records are not merged.
Read the complete study conditions, biological results, tolerability and figures →
References
- Baek R, et al. Characterizing the mechanism of action for mRNA therapeutics for the treatment of propionic acidemia, methylmalonic acidemia, and phenylketonuria. Nature Communications 15, 3804 (2024).
- Supplementary Information: formulation distinctions and Tables 1–10.
- Source Data accompanying the article.